Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AHRQ, FDA to study cardiovascular risks of ADHD drugs

The Department of Health and Human Services' Agency for Healthcare

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE